According to the Zhitong Finance App, Shanghai Kaibao (300039.SZ) announced that the company and its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. (“Xinyi Pharmaceutical”) have included a total of 93 drugs in the national health insurance catalogue, including 50 category A and 43 category B. It mainly involves 3 exclusive varieties (the company's product: Phlegm Fever Clear Injection, Phlegm Fever Clear Capsule, and subsidiary product: Astragalus Capsule), and 1 exclusive dosage form (the company's product, Dosofylline capsule), etc., which continues to enter the “National Medical Insurance Catalogue (2023)”.

Among them, in the “National Medical Insurance Catalogue (2023)”, the scope of medical insurance payments for some proprietary Chinese medicines in the “National Medical Insurance Catalogue (2023)” was adjusted from “limited to severe patients in grade 2 and above medical institutions” to “limited to medical institutions of grade 2 and above”; the company's exclusive variety of phlegm and cleansing capsules continued to be included in the “National Health Insurance Catalogue (2023)” through negotiation and renewal, and the medical insurance payment standard is 4.09 yuan/ (0.4 g/capsule). The agreement is valid from January 1, 2024 to December 31, 2025. After the expiration of the validity period, it will be adjusted again according to relevant medical insurance regulations. The inclusion of the company's other products in the “National Health Insurance Catalogue (2023)” remains the same as the “National Health Insurance Catalogue (2022)”.